Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
NCT ID: NCT00450593
Last Updated: 2013-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
5000 participants
OBSERVATIONAL
1989-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying gene mutations in patients with melanoma and in families with a history of hereditary melanoma.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the incidence and etiologic significance of variants of known melanoma susceptibility genes (MSGs) in families with multiple cases of melanoma.
* Determine the proportion of multiple-case families that are explained by high-penetrance mutations in known MSGs.
* Determine the proportion of multiple-case families that are explained by these mutations and whether it varies with latitude, as a surrogate for ultraviolet exposure, with number of affected relatives, with average age at onset of melanoma in relatives, with presence of multiple primary melanoma, or with other family-specific variables.
* Determine the penetrance of MSG mutations in these families.
* Determine if the penetrance varies with age, sex, or birth cohort.
* Determine if the penetrance varies with the gene involved or nature of the mutation.
* Assess the penetrance in mutations that also have a deleterious effect on the alternative splice product, p14ARF.
* Determine whether carriers of MSGs have an increased susceptibility to other types of cancer.
* Determine the risk of other types of cancers for mutation carriers.
* Determine environmental exposures, in particular sun exposure, that modify risk of melanoma in MSG mutation carriers.
* Determine the cutaneous phenotypes that correlate with melanoma risk in these families.
* Correlate cutaneous phenotypes with the presence of MSG variants.
* Determine the effect of other covariates, such as sun exposure or the presence of alleles of putative modifying genes (e.g., MC1R or CDKN2A), on phenotype.
* Determine if modifier genes, such as those controlling pigmentation of the skin, and therefore sun susceptibility, modify risk in MSG mutation carriers.
* Identify any histopathological correlates of MSG status in primary tumors arising in melanoma-susceptible individuals in these families.
* Identify any histopathological correlates of primary melanomas in carriers of MSG mutations with other covariates.
OUTLINE: This is a case-control, multicenter study.
Participants complete 2 questionnaires and assist in the creation and expansion of a family pedigree. Blood samples are examined for melanoma susceptibility gene mutations, including CDK4 and CDKN2A.
Participants are also examined for moles and photographed. Physical variables (e.g., skin, eye, and hair pigmentation) and sun damage (solar lentigines and freckling) are also noted.
If available, tissue samples are examined for Clark level, Breslow thickness, and frequency of mitoses. Peri-lesional skin from tumors is examined by p53 staining.
Participants are followed periodically to monitor cancer development.
Peer reviewed and funded or endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 5,000 participants will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gene expression analysis
microarray analysis
molecular genetic technique
mutation analysis
laboratory biomarker analysis
mutation carrier screening
study of high risk factors
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meets one of the following criteria:
* Prior multiple primary melanomas
* Histological samples available
* Family history of melanoma, with melanoma in two first-degree relatives (e.g., cases of melanoma in both a mother and son or in two brothers but not in two cousins)
* Family history of melanoma, where three or more individuals (of any relationship) have had melanoma
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Leeds Cancer Centre at St. James's University Hospital
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julia Newton Bishop, MD
Role: STUDY_CHAIR
Leeds Cancer Centre at St. James's University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leeds Cancer Centre at St. James's University Hospital
Leeds, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Julia Newton Bishop, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDR0000532941
Identifier Type: REGISTRY
Identifier Source: secondary_id
EU-20705
Identifier Type: -
Identifier Source: secondary_id
CRUK-LCC-99/3/45
Identifier Type: -
Identifier Source: org_study_id